{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:32:30Z","timestamp":1790908350531,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jcyt.2025.102044","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T07:19:50Z","timestamp":1766647190000},"page":"102044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lipid nanoparticle\u2014points to consider in assessing materials quality for ribonucleic acid-based therapeutics"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7688-5560","authenticated-orcid":false,"given":"Sita","family":"Somara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Heidaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2025.102044_bib0001","article-title":"World\u2019s first personalized CRISPR therapy given to baby with genetic disease","author":"Ledford","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2025.102044_bib0002","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/mas.21856","article-title":"Characterization of mRNA therapeutics","volume":"43","author":"Guimaraes","year":"2024","journal-title":"Mass Spectrom Rev"},{"key":"10.1016\/j.jcyt.2025.102044_bib0003","unstructured":"McCarthy D. Assessing quality of mRNA vaccines: key considerations. 2022 [cited 2025 Jul 31]. Available from: https:\/\/www.bioprocessonline.com\/doc\/assessing-quality-of-mrna-vaccines-key-considerations-0001"},{"key":"10.1016\/j.jcyt.2025.102044_bib0004","unstructured":"Josephson F. Rapporteur rolling review critical assessment report assessment report on the claim of new active substance (NAS) status of 5\u2032 capped mRNA encoding full length SRAS-CoV-2 Spike protein contained in COVID-19 mRNA vaccine BioNTech date of the revised report date of final report. 2020 [cited 2025 Jul 31]; Available from: https:\/\/voorwaarheid.nl\/wp-content\/uploads\/2022\/12\/Rapporteurs-Rolling-Review-Report-New-Active-Substance-Status-COVID-19-mRNA-Vaccine-BioNTec.pdf"},{"key":"10.1016\/j.jcyt.2025.102044_bib0005","unstructured":"FDA Center for Biologics Evaluation and Research (CBER). BLA clinical review memorandum application type biologics license application (BLA) STN 125752\/0 CBER. 2022 [cited 2025 Jul 31]. Available from: https:\/\/www.fda.gov\/media\/156342\/download"},{"key":"10.1016\/j.jcyt.2025.102044_bib0006","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12929-023-00977-5","article-title":"mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications","volume":"30","author":"Wang","year":"2023","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.jcyt.2025.102044_bib0007","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jcyt.2025.102044_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113945","article-title":"Impact of ionizable lipid type on the pharmacokinetics and biodistribution of mRNA-lipid nanoparticles after intravenous and subcutaneous injection","volume":"384","author":"Ren","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.jcyt.2025.102044_bib0009","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials of mRNA vaccines for cancer treatment","volume":"23","author":"L Lorentzen","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2025.102044_bib0010","unstructured":"Verve Therapeutics. Verve data [cited 2025 Jul 31]. Available from: https:\/\/www.vervetx.com\/our-programs\/verve-102"},{"key":"10.1016\/j.jcyt.2025.102044_bib0011","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41587-022-01304-3","article-title":"Reflections on Alnylam","volume":"40","author":"Maraganore","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2025.102044_bib0012","unstructured":"FDA Center for Drug Evaluation and Research (CDER). Summary review\u2014Amvuttra (vutrisiran). 2022 [cited 2025 Jul 31]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/215515Orig1s000SumR.pdf"},{"key":"10.1016\/j.jcyt.2025.102044_bib0013","unstructured":"Padda IS, Mahtani AU, Patel P, Parmar M. Small interfering RNA (siRNA) therapy. 2024 [cited 2025 Jul 31]; Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK580472\/. PMID: 35593797."},{"key":"10.1016\/j.jcyt.2025.102044_bib0014","unstructured":"FDA Center for Drug Evaluation and Research (CDER). Product quality review(s): Onpattro (patisiran). 2017 [cited 2025 Jul 31]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210922Orig1s000ChemR.pdf"},{"key":"10.1016\/j.jcyt.2025.102044_bib0015","doi-asserted-by":"crossref","first-page":"367","DOI":"10.14348\/molcells.2016.0039","article-title":"Incredible RNA: dual functions of coding and noncoding","volume":"39","author":"Nam","year":"2016","journal-title":"Mol Cells"},{"key":"10.1016\/j.jcyt.2025.102044_bib0016","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1093\/nar\/13.20.7375","article-title":"The effect of capping and polyadenylation on the stability, movement and translation of synthetic messenger RNAs in Xenopus oocytes","volume":"13","author":"Drummond","year":"1985","journal-title":"Nucleic Acid Res"},{"key":"10.1016\/j.jcyt.2025.102044_bib0017","article-title":"Intrinsically unstructured sequence in the mRNA 3\u2032 UTR reduce the ability of poly(A) tail to enhance","volume":"434","author":"Lai","year":"2022","journal-title":"Translation J Mol Biol"},{"key":"10.1016\/j.jcyt.2025.102044_bib0018","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","article-title":"N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice","volume":"217","author":"Andries","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.jcyt.2025.102044_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111917","article-title":"CRISPR: history and perspectives to the future","volume":"141","author":"Kozovska","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jcyt.2025.102044_bib0020","unstructured":"United States Pharmacopeia (USP). Monograph\u20141,2-distearoyl-sn-glycero-3-phosphocholine [cited 2025 Jul 31]; Available from: https:\/\/doi.usp.org\/USPNF\/USPNF_M16917_10101_01.html"},{"key":"10.1016\/j.jcyt.2025.102044_bib0021","unstructured":"United States Pharmacopeia (USP). Monograph\u2014cholesterol. 2024 [cited 2025 Jul 31]. Available from: https:\/\/doi.usp.org\/USPNF\/USPNF_M17220_03_01.html"},{"key":"10.1016\/j.jcyt.2025.102044_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jcyt.2025.102044_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/EXP.20230147","article-title":"A perspective of lipid nanoparticles for RNA delivery","volume":"4","author":"Ma","year":"2024","journal-title":"Exploration"},{"key":"#cr-split#-10.1016\/j.jcyt.2025.102044_bib0024.1","doi-asserted-by":"crossref","unstructured":"Lee Y, Jeong M, Park J, Jung H, Lee H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. 2023 [cited 2025 Jul 31]","DOI":"10.1038\/s12276-023-01086-x"},{"key":"#cr-split#-10.1016\/j.jcyt.2025.102044_bib0024.2","doi-asserted-by":"crossref","unstructured":"Available from: https:\/\/doi.org\/10.1038\/s12276-023-01086-x. Epub 2023 Oct 2. PMID: 37779140.","DOI":"10.1038\/s12276-023-01086-x"},{"key":"10.1016\/j.jcyt.2025.102044_bib0025","unstructured":"US Food and Drug Administration. Q7 good manufacturing practice guidance for active pharmaceutical ingredients guidance for industry. 2016 [cited 2025 Jul 31]. Available from: https:\/\/www.fda.gov\/media\/71518\/download"},{"key":"10.1016\/j.jcyt.2025.102044_bib0026","unstructured":"US Food and Drug Administration. Nonclinical studies for the safety evaluation of pharmaceutical excipients\u2014guidance for industry. 2005 [cited 2025 Jul 31]. Available from: https:\/\/www.fda.gov\/media\/72260\/download"},{"key":"10.1016\/j.jcyt.2025.102044_bib0027","unstructured":"FDA Center for Drug Evaluation and Research O of ND (CDER\/OND). Pilot program for the review of innovation and modernization of excipients (PRIME). 2022 [cited 2025 Jul 31]. Available from: https:\/\/content.govdelivery.com\/accounts\/USFDA\/bulletins\/2f02897"},{"key":"10.1016\/j.jcyt.2025.102044_bib0028","unstructured":"FDA Center for Biologics Evaluation and Research (CBER). Chemistry, manufacturing, and controls changes to an approved application: certain biological products; guidance for industry. 2021 [cited 2025 Jul 31]. Available from: https:\/\/www.fda.gov\/media\/109615\/download"},{"key":"10.1016\/j.jcyt.2025.102044_bib0029","unstructured":"Health Canada. Guidance document post-notice of compliance (NOC) changes: quality document. 2009 [cited 2025 Jul 31]; Available from: https:\/\/www.canada.ca\/content\/dam\/hc-sc\/documents\/services\/drugs-health-products\/drug-products\/applications-submissions\/guidance-documents\/post-notice-compliance-changes\/quality-document\/quality-document.pdf"},{"key":"10.1016\/j.jcyt.2025.102044_bib0030","unstructured":"FDA Center for Biologics Evaluation and Research (CBER). Human gene therapy products incorporating human genome editing; guidance for industry. 2024 [cited 2025 Jul 31]. Available from: https:\/\/www.fda.gov\/media\/156894\/download"},{"key":"10.1016\/j.jcyt.2025.102044_bib0031","unstructured":"FDA Center for Biologics Evaluation and Research (CBER). Chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs) guidance for industry. 2020 [cited 2025 Jul 31]; Available from: https:\/\/www.fda.gov\/media\/113760\/download"},{"key":"10.1016\/j.jcyt.2025.102044_bib0032","unstructured":"European Medicines Agency (EMA). Draft guideline on the quality aspects of mRNA vaccines. 2025 [cited 2025 Aug 7]; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-quality-aspects-mrna-vaccines_en.pdf"},{"key":"10.1016\/j.jcyt.2025.102044_bib0033","unstructured":"FDA Center for Drug Evaluation and Research (CDER). Drug products, including biological products, that contain nanomaterials\u2014guidance for industry. 2022 [cited 2025 Jul 31]. Available from: https:\/\/www.fda.gov\/media\/157812\/download"},{"key":"10.1016\/j.jcyt.2025.102044_bib0034","unstructured":"FDA Center for Biologics Evaluation and Research (CBER). Platform technology designation program for drug development\u2014draft guidance for industry. 2024 [cited 2025 Aug 7]. Available from: https:\/\/www.fda.gov\/media\/178938\/download"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925009405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925009405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:18:08Z","timestamp":1782199088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925009405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1465324925009405"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.102044","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid nanoparticle\u2014points to consider in assessing materials quality for ribonucleic acid-based therapeutics","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.102044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102044"}}